Related Experiment Videos
Type 1 diabetes islet autoantibody markers.
William E Winter1, Neil Harris, Desmond Schatz
1Department of Pathology, Laboratory Medicine & Immunology, University of Florida, Gainesville, Florida 32610-0275, USA. winter@pathology.ufl.edu
Diabetes Technology & Therapeutics
|March 5, 2003
Summary
Identifying islet autoantibodies is crucial for diagnosing type 1 diabetes and predicting its onset. These biomarkers aid in distinguishing diabetes types and may inform future prevention strategies.
Area of Science:
- Endocrinology
- Immunology
- Diabetology
Background:
- Accurate diagnosis of type 1 diabetes (T1D) is essential for appropriate treatment.
- Distinguishing T1D from other diabetes types, like type 2 diabetes, presents clinical challenges.
Purpose of the Study:
- To highlight the diagnostic and predictive roles of islet autoantibodies in T1D.
- To discuss the clinical utility of specific islet autoantibodies.
Main Methods:
- Review of identified islet autoantibodies.
- Analysis of their diagnostic and predictive capabilities in various patient populations.
Main Results:
- Several islet autoantibodies, including islet cell cytoplasmic autoantibodies, insulin autoantibodies, glutamic acid decarboxylase autoantibodies, and insulinoma-associated-2 autoantibodies, are valuable diagnostic and predictive markers.
- These autoantibodies help diagnose immune-mediated T1D in ambiguous cases and predict T1D in non-diabetic individuals.
Conclusions:
- Islet autoantibodies are critical for diagnosing and predicting type 1 diabetes.
- Large-scale screening may be warranted if T1D prevention becomes feasible.
- The influence of islet autoantibodies on T1D progression post-diagnosis remains under investigation.